COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones.
The expiration of enhanced ACA subsidies has created a subsidy cliff, leaving some facing much higher premiums and potential tax surprises if they're not careful.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback